Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Selegiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 11/20 | 1.00 |
| ▸ | MAOA | P21397 | 8/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | SNCA | P37840 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Selegiline SCHEMBL15867136 | 1.00 | MAOB (1.00) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL12248117 | 1.00 | MAOB (1.00) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL22232 | 1.00 | MAOB (1.00) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL1286950 | 1.00 | MAOB (1.00) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL5499736 | 1.00 | MAOB (1.00) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL41392 | 0.98 | MAOB (1.00) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL473659 | 0.98 | MAOB (1.00) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL1171497 | 0.97 | MAOB (0.93) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL7105217 | 0.97 | MAOB (0.93) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL4611911 | 0.95 | MAOB (0.90) | MAOBMAOACYP1A2ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6998 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059788-A | Production process and system of high-purity dicyclopentadiene | 中国石油天然气股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-12560618-B2 | Innate immune proteins as biomarkers for CNS injury | UNIVERSITY OF MIAMI (US) | 2026-02-24 | — | — | US | claimed |
| US-20250235641-A1 | DEVICE TO DELIVER A PREDETERMINED AMOUNT OF A SUBSTANCE TO A NATURAL ORIFICE OF THE BODY | APTARGROUP INC. (US) | 2025-07-24 | — | — | US | claimed |
| US-12178798-B2 | Methods to grow then harvest and process insects | INSECTERGY LLC (US) | 2024-12-31 | — | — | US | claimed |
| US-20240350455-A1 | COMPOSITIONS AND METHODS COMPRISING A COMBINATION OF SEROTONERGIC DRUGS | CAAMTECH, INC. (US) | 2024-10-24 | — | — | US | claimed |
| WO-2024206503-A2 | METHODS, COMPOSITIONS FOR TREATMENT, BIOMARKERS, AND DIAGNOSIS FOR COLORECTAL CANCER | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-10-03 | — | — | WO | claimed |
| US-20240216336-A1 | CLOTRIMAZOLE AS A TREATMENT FOR IMMUNODEFICIENCY DISORDERS | NORTHWESTERN UNIVERSITY | 2024-07-04 | — | — | US | claimed |
| US-11938119-B2 | Cannabis production systems and methods | INSECTERGY, LLC (US) | 2024-03-26 | — | — | US | claimed |
| US-20240060995-A1 | INNATE IMMUNE PROTEINS AS BIOMARKERS FOR TRAUMATIC BRAIN INJURY IN ADULT AND PEDIATRIC PATIENTS | UNIV MIAMI (US) | 2024-02-22 | — | — | US | claimed |
| EP-0440704-A1 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWEL SYMPTOMS. | MASSACHUSETTS INST TECHNOLOGY (US) | 1991-08-14 | — | — | EP | claimed |
| EP-0386117-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-09-12 | — | — | EP | claimed |
| WO-1990004387-A2 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-05-03 | — | — | WO | claimed |
| US-4861800-A | Method for administering the drug deprenyl so as to minimize the danger of side effects | SOMERSET PHARMACEUTICALS, INC., A CORP. OF DELAWARE | 1989-08-29 | — | — | US | claimed |
| WO-1989003692-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-05-05 | — | — | WO | claimed |
| US-4826875-A | Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 1989-05-02 | — | — | US | claimed |
| US-4722940-A | Aminoalkyl phenyl selenides for the treatment of hypertension and nervous system dysfunctions | GEORGIA TECH RESEARCH CORPORATION (US) | 1988-02-02 | — | — | US | claimed |
| EP-0252290-A2 | Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof | CHIESI FARMACEUTICI S.p.A. (IT) | 1988-01-13 | — | — | EP | claimed |
| US-4579870-A | Aminoalkyl phenyl selenides for the treatment of hypertension and nervous system dysfunctions | GEORGIA TECH RESEARCH CORPORATION (US) | 1986-04-01 | — | — | US | claimed |
| US-4415591-A | MIXTURE WITH A MONOAMINE OXIDASE | GEORGIA TECH RESEARCH INSTITUTE (US) | 1983-11-15 | — | — | US | claimed |